chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 52.0
Sex: M
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: Broke out in Hives / welts on arms, legs , lower back and rump; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 11Apr2021 at 14:15 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Medical history included small stroke in 2018. The patient had no known allergies to medications, food or other products. Concomitant medications included atorvastatin (MANUFACTURER UNKNOWN) and sildenafil (MANUFACTURER UNKNOWN); both taken for unspecified indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 21Mar2021 at 15:00 (at the age of 52-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19.  Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 18Apr2021 at 22:00, the patient broke out in hives while sleeping, it continued nightly through 23Apr2021 with welts on arms, legs, lower back and rump that went away during the day and flared up while asleep. The patient reported that he had contacted his dermatologist. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. It was unknown whether any therapeutic measures were taken as a result of the events. The clinical outcome of the event hives with welts on arms, legs, lower back and rump were not resolved at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 36.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Pain, Pyrexia
Clinical narrative: 1st shot was fine, after 2nd shot had body aches, fever of 102, chills; 1st shot was fine, after 2nd shot had body aches, fever of 102, chills; 1st shot was fine, after 2nd shot had body aches, fever of 102, chills; This is a spontaneous report from a non-contactable consumer, the patient. A 36-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 21Apr2021 at 17:15 (at the age of 36-years-old) as a single dose for COVID-19 immunisation. The patient had no other medical history. The patient had no known allergies to medications, food, or other products. Concomitant medications taken within two weeks of vaccination included escitalopram (MANUFACTURER UNKNOWN) and norethisterone (NORETHINDRONE); both from unknown date for unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 31Mar2021 (at the age of 36-years-old) as a single dose for COVID-19 immunisation and was fine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. First shot, the patient was fine, after second shot, the patient had body aches, fever of 102 (units unspecified), chills on 22Apr2021. Therapeutic measures were not taken as a result of the events. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events after second shot had body aches, fever of 102 (units unspecified), chills was resolving at the time of this report.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 34.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Pain in extremity
Clinical narrative: Pain in left leg and back; Pain in left leg and back; This is a spontaneous report from a non-contactable consumer, the patient. A 34-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the left arm on 13Apr2021 at 10:00 (at the age of 34-year-old) as a single dose for COVID-19 immunisation. The patient had no relevant medical history. The patient had no known allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included vitamins (MANUFACTURER UNKNOWN) for an unknown indication from an unknown date. On 20Apr2021 at 13:00, the patient experienced pain in left leg and back. The event resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of the events and the patient would see a doctor on the day of report. The clinical outcome of the events pain in left leg and back were resolving at the time of the report.  No follow-up attempts are possible. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Migraine
Clinical narrative: The patient experienced a migraine; This is a spontaneous report from a non-contactable consumer. A female patient of unknown age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 22Apr2021 as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. It was unknown whether the patient received any other vaccines within four weeks prior to the vaccination. On 23Apr2021, the next day after receiving the second dose of the vaccine the patient experienced a migraine. The event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. It was unknown whether therapeutic measures were taken as a result of the event. Since the vaccination, it was unknown whether the patient had been tested for COVID-19.The clinical outcome of the event migraine  was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Erythema, Herpes zoster, Pain
Clinical narrative: Shingles pain (mild to moderate) in the upper back and torso; Redness; shingles pain (mild to moderate) in theupper back and torso; This is a spontaneous report from a contactable consumer, the patient. A 52-year-old, non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Er8730) via an unspecified route od administration on 01Apr2021 at 17:00 in the left arm (at the age of 52-years-old) as single dose for COVID-19 immunisation. Medical history included autoimmune NOS, shingles event April 2020 and environmental allergies. Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccination within 4 weeks prior to COVID vaccine. Concomitant medication included colecalciferol (VITAMIN D3), CENTRUM WOMEN and vitamin b complex (B-COMPLEX); all for unspecified indication and start date. On 03Apr2021, started with 48 hours post vaccine, the patient experienced shingles pain (mild to moderate) in the upper back and torso, redness and had no visible rash. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of the events with unspecified topical cream and otc acetaminophen. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events of shingles pain (mild to moderate) in the upper back and torso and redness were not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 16.0
Sex: F
Vaccine: COVID19
Symptoms: Eye pruritus, Eye swelling, Ocular hyperaemia, Swelling face
Clinical narrative: eyes began itching in the middle of the night; woke up with red swollen eyes; woke up with red swollen eyes; swollen face; This is a spontaneous report from a contactable consumer, the patient. A 16-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731) via an unspecified route of administration in the left arm on 20Apr2021 at 14:00 (at the age of 16-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant past medical history. The patient had no known allergies to medications, food or other products. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021, at 00:00 the patient experienced eyes began itching in the middle of the night. On 21Apr2021, the patient woke up with red swollen eyes and a swollen face. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events eyes began itching in the middle of the night, red swollen eyes and swollen face were recovered on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal discomfort, Fatigue, Headache, Pain, Pyrexia
Clinical narrative: Moderate body pain; Fatigue; Mild headache; Low fever; Upset stomach; This is a spontaneous report from a contactable healthcare professional, the patient. A 56-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the right arm on 20Apr2021 at 14:30 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included allergy, depression, anxiety and pre-diabetes. The patient had unspecified allergies to medications, food, or other products. Concomitant medications included losartan (MANUFACTURER UNKNOWN), duloxetine hydrochloride (DULOXETINE DR), lisdexamfetamine mesilate (VYVANSE) and buspirone (MANUFACTURER UNKNOWN), all taken for unspecified indications from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 31Mar2021 at 15:00 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 21Apr2021 at 06:30, the patient experienced moderate body pain, fatigue, mild headache, low fever and upset stomach. Therapeutic measures were taken as a result of the events and included treatment with Over-The-Counter (OTC) medication Aleve. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. The clinical outcome of the events moderate body pain, fatigue, mild headache, low fever and upset stomach were resolved on an unknown date in Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Peripheral swelling
Clinical narrative: Swollen fingers; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER873-) via an unspecified route of administration in the left arm on 19Apr2021 at 13:30 (at the age of 31-year-old) as a single dose for COVID-19 immunisation. The patient had no medical history. The patient had no known allergies to food, medications or other products. The patient did not receive any medication within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the left arm on 29Mar2021 at 13:30  (at the age of 31-year-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Apr2021 at 12:00 the patient experienced swollen fingers . The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event swollen fingers  was recovered on 20Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Chills, Fatigue, Headache, Lymphadenitis
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 32-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO158) via an unspecified route of administration in the left arm on 21Apr2021 at 10:00 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO150) via an unspecified route of administration in the left arm on 31Mar2021 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. On 21Apr2021 at 21:00, the patient experienced temperature of 101.3 (unit unspecified), fever including shakes, chills, vomiting, pain in the injection site, myalgia, inflamed lymph node behind the right ear, headache and fatigue. It was reported that these events lasted for 36 hours however, fatigue and inflamed lymph node behind the right ear were ongoing but the patient was generally healthy. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events temperature of 101.3/ fever, shakes, chills, vomiting, pain in the injection site, myalgia and headache was recovered on 23Apr2021 at 09:00 while outcome of the events inflamed lymph node behind the right ear and fatigue was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Myalgia, Pyrexia, Tremor, Vaccination site pain, Vomiting
Clinical narrative: This is a spontaneous report from a contactable consumer, the patient. A 32-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO158) via an unspecified route of administration in the left arm on 21Apr2021 at 10:00 (at the age of 32-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO150) via an unspecified route of administration in the left arm on 31Mar2021 (at the age of 32-year-old) as a single dose for COVID-19 immunisation. On 21Apr2021 at 21:00, the patient experienced temperature of 101.3 (unit unspecified), fever including shakes, chills, vomiting, pain in the injection site, myalgia, inflamed lymph node behind the right ear, headache and fatigue. It was reported that these events lasted for 36 hours however, fatigue and inflamed lymph node behind the right ear were ongoing but the patient was generally healthy. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events temperature of 101.3/ fever, shakes, chills, vomiting, pain in the injection site, myalgia and headache was recovered on 23Apr2021 at 09:00 while outcome of the events inflamed lymph node behind the right ear and fatigue was recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: Lip pain, Lip swelling, Mouth swelling, Oral discomfort, Oral pain
Clinical narrative: lips began burning; lips swelling; Lips pain; Painful mouth; burning, swelling, and hurting a lot. Its spreading to the rest of my mouth.; swelling, and hurting a lot. Its spreading to the rest of my mouth.; This is a spontaneous report from a contactable other healthcare professional, the patient. A 43-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 18Apr2021 at 09:15 (at the age of 43-year-old) as a single dose for COVID-19 immunisation. Medical history included celiac disease and gluten allergy. The patient previously took erythromycin (MANUFACTURER UNKNOWN) and metoclopramide (REGLAN) both were from unknown date for unknown indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included bupropion hydrochloride (WELLBUTRIN) from 2005 and for unknown indication. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Apr2021, Tuesday morning at 08:00 the patient  lips started burning, swelling, and hurting a lot. It was spreading to the rest of mouth and it was quite painful, although it was not anaphylaxis and definitely not life threatening. However, it continues to get slowly and steadily worse. The patient had severe celiacs disease, so the patient eats the same foods every day and never alter those meals, even down to the smallest ingredients. He was aware of everything that touches his skin. He was sorry to say but there really isn't anything else that could be causing this. Since the vaccination, the patient had not been tested for COVID-19. The events resulted in emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events lips began burning, swelling, and hurting a lot mouth painful, mouth burning and mouth swelling were not resolved at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: Body temperature, Lymphadenopathy, Migraine, Pyrexia, Ultrasound scan
Clinical narrative: Lymph nodes under the left armpit grew enormously large, there is clearly an inflammation and it hurts a lot; Migraine; Temperature over 100; This is a spontaneous report from a contactable consumer, the patient. A 35-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via an unspecified route of administration in the left arm on 20Apr2021 at 12:15 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. Medical history included an allergy to cats. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications were not reported. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the left arm on 30Mar2021 at 12:30 (at the age of 35-years-old) as a single dose for COVID-19 immunisation. On 21Apr2021 at 06:00, the patient experienced migraine, temperature over 100 and lymph nodes under the left armpit grew enormously large, there was clearly an inflammation and it hurt a lot. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. On 21Apr2021 at 06:00, the patient underwent test for body temperature and the result was fever with temperature over 100. On an unknown date in Apr2021, the patient underwent lab tests and procedures, which included ultrasounds exam and the result was several large nodes up to 3 cm. Therapeutic measures were taken as a result of events and included treatment with ibuprofen (MANUFACTURER UNKNOWN). The clinical outcome for the events migraine, fever and swollen lymph nodes were unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity, Rash, Skin odour abnormal
Clinical narrative: Large rash on right arm; Sore on right arm; Sore on right hand knuckle; Stunk when washed hands; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ew0162) via an unspecified route of administration in the left arm on 13Apr2021 at 15:30 (at the age of 51-years-old), as a single dose for COVID-19 immunisation. Medical history included allergic reaction to bee sting. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient received unspecified medications within two weeks of vaccination. On 22Apr2021 at 17:00, the patient experienced a sore on her right-hand knuckle, and it stunk when she washed her hands, Cleaned it out with peroxide. The patient went to bed at 23:00. On 23Apr2021 at 04:00, the patient woke up and went into the bathroom turned on the light and saw another sore on her right arm and large rash on her right arm. She went back to bed and woke up about 8:00 and rash had shrunk to half its size. It doesn't itch. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events sore on right hand knuckle, stunk when washed the hands, sore on right arm and large rash on right arm were not resolved at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Chills, Dizziness, Headache, Nausea
Clinical narrative: Severe pain in lower back; Dizzy; Headache; Fever; Chills; Nauseous; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8735) via an unspecified route of administration in the right arm on 21Apr2021 at 08:30 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. Medical history included unspecified allergy to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications. The patient previously received the first dose of BNT162b2 ((PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8733) via an unspecified route of administration in the right arm on 31Mar2021 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. On 21Apr2021 at 08:45, the patient experienced headache, fever, chills, severe pain in lower back, dizzy and nauseous. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events headache, fever, chills, severe pain in lower back, dizzy and nauseous were resolving at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: Severe pain in lower back; Dizzy; Headache; Fever; Chills; Nauseous; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8735) via an unspecified route of administration in the right arm on 21Apr2021 at 08:30 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. Medical history included unspecified allergy to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any concomitant medications. The patient previously received the first dose of BNT162b2 ((PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8733) via an unspecified route of administration in the right arm on 31Mar2021 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. On 21Apr2021 at 08:45, the patient experienced headache, fever, chills, severe pain in lower back, dizzy and nauseous. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events headache, fever, chills, severe pain in lower back, dizzy and nauseous were resolving at the time of the report.  No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Pain, Vaccination site pain
Clinical narrative: Body aches; Joint pain; Vaccination site pain and soreness; This is a spontaneous report from a contactable consumer, the patient. A 39-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0153) via an unspecified route of administration in the left arm on 13Apr2021 at 10:15 (at the age of 39-year-old) as a single dose for COVID-19 immunisation. Medical history included seasonal allergy. The patient previously took amoxicillin on an unknown date for unknown indication and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included fexofenadine hydrochloride (ALLEGRA) and allergy shots from an unknown date for unknown indication and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 12:00 the patient experienced body aches and joint pain for 24 hours, injection site pain and soreness for 4days. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events body aches, joint pain were recovered on15Apr2021. The clinical outcome of the event injection site pain and soreness was recovered on 17Apr2021.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Insomnia
Clinical narrative: Insomnia for several days; This is a spontaneous report from a non-contactable consumer. A 39-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date (at the age of 39-years-old) as a single dose for COVID-19 immunisation. Medical history included known allergies which were unspecified. It was unknown if the patient was pregnant at the time vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. It was unknown if the patient received any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medications were not reported. On an unknown date, the patient experienced insomnia for several days. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event insomnia for several days was recovered on an unknown date.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Amnesia, Feeling abnormal
Clinical narrative: still foggy; some short term memory issues; This is a spontaneous report from a contactable consumer, the patient. A 54-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9264) via an unspecified route of administration in the right arm on 24Mar2021 at 17:30 (at the age of 54-years-old) as a single dose for COVID-19 immunisation. Medical history included blood pressure and allergy. Concomitant medications included unspecified medications for blood pressure and allergy, taken from unknown dates. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on an unknown date as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 24Mar2021 at 18:45, the patient experienced foggy which was still present at the time of this report and had some short-term memory issues. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events foggy and short-term memory issues were resolved with sequelae on unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 41.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Fatigue, Pyrexia
Clinical narrative: Chills; Fever 100.5; "Intense fatigu"; This is a spontaneous report from a contactable consumer, the patient. A 41-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 21Apr2021 at 17:30 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. The patients' medical history included a known allergy to sulfa (sulfonamide) drugs. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medication included progesterone (PROMETRIUM) taken for an unknown indication from an unknown date and unknown if ongoing. The patient previously received amoxicillin (MANUFACTURER UNKNOWN) and experienced a drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8734) via an unspecified route of administration in the left arm on 31Mar2021 at 16:30 (at the age of 41-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccination. On 22Apr2021 at 14:00, the patient experienced chills, fever 100.5 (unspecified units) and "intense fatigu". The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of these events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events chills, fever 100.5 (unspecified units) and "intense fatigu" were resolving at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 77.0
Sex: F
Vaccine: COVID19
Symptoms: Gait disturbance, Pain, Sciatica, Sleep disorder
Clinical narrative: Debilitating pain mostly on the right side of body from hip to foot, inside of knees on both legs, left shin, front and back of left leg; Shooting pain is similar to sciatica; Pain caused to quit walking and doing exercises; Sometimes the pain wakes up at night; This is a spontaneous report from a contactable consumer, the patient. A 77-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198) via an unspecified route of administration in the left arm on 20Feb2021 at 10:00 (at the age of 77-years-old) as a single dose for COVID-19 immunisation. Medical history included hypertension and iodine allergy (internal). Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Concomitant medication included hydrochlorothiazide/losartan potassium (MANUFACTURER UNKNOWN) "100'' for an unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL1283) via an unspecified route of administration in the left arm on 24Jan2021 at 10:00 (at the age of 77-years-old) as a single dose for COVID-19 immunisation. The patient previously received oxycodone/aspirin (PERCODAN), lorsartan potassium (MANUFACTURER UNKNOWN), ketotifen fumarate (ZADITOR EYE DROPS) and amlodipine (MANUFACTURER UNKNOWN) and experienced drug allergy. On an unknown date in Mar2021, the patient experienced debilitating pain mostly on the right side of body from hip to foot, inside of knees on both legs, left shin, front and back of left leg. Sometimes, shooting pain was similar to sciatica which caused to quit walking and doing exercises. Walking up and down stairs was painful and it bothered the patient mostly at night when lying in bed. Sometimes, the pain woke her up at night. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result adverse events and included unspecified treatment which was ongoing. The clinical outcome of the events debilitating pain mostly on the right side of body from hip to foot, inside of knees on both legs, left shin, front and back of left leg, shooting pain was similar to sciatica and pain caused to quit walking and doing exercises and sometimes the pain wakes her up at night were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 24.0
Sex: F
Vaccine: COVID19
Symptoms: Pain in extremity
Clinical narrative: Pain in arm; This is a spontaneous report from a non-contactable consumer, the patient. A 24-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 09Apr2021 at 18:45 (at the age of 24-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via an unspecified route of administration in the left arm on 12Mar2021 at 18:45 (at the age of 23-year-old) as a single dose for COVID-19 immunisation. On 20Apr2021 at 16:15, (also reported as 2 weeks later), the patient experienced pain in arm. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Since the vaccination the patient had not been tested for COVID-19.  Therapeutic measures were not taken as a result of the event. The clinical outcome of the event pain in arm was unknown at the time of the report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
Age: 24.0
Sex: M
Vaccine: COVID19
Symptoms: Rash, Rash erythematous
Clinical narrative: Developed a rash/ developing a rash every day since vaccine/ The rash has been getting bigger and appearing on various parts of the body; The rash is red not raised, originally not itchy, but becoming more each day; This is a spontaneous report from a contactable pharmacist. A 24-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6206) via intramuscular route of administration in the left arm on 19Apr2021 at 11:00 (at the age of 24-year-old) as a single dose for COVID-19 immunisation. Medical history included COVID-19. Prior to the vaccination, the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications were not reported. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL3302) via intramuscular route of administration in the right arm on 29Mar2021 at 11:00 (at the age of 24-year-old) as a single dose for COVID-19 immunisation. On 19Apr2021, the patient developed a rash. The patient was developing a rash every day since vaccine. The rash has been getting bigger and appearing on various parts of the body and the rash was red, not raised, originally not itchy, but becoming more each day. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19. Therapeutic measures were taken as a result of events and included treatment with diphenhydramine hydrochloride (BENADRYL). The clinical outcome of the event developed a rash, developing a rash every day since vaccine, rash has been getting bigger and appearing on various parts of the body and the rash was red, not raised, originally not itchy, but becoming more each day were not recovered at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 31.0
Sex: F
Vaccine: COVID19
Symptoms: Anosmia
Clinical narrative: Loss of smell; This is a spontaneous report from a contactable consumer, the patient. A 31-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EW0170) via an unspecified route of administration in the left arm on 21Apr2021 at 12:15 (at the age of 31-years-old) as a single dose for COVID-19 immunisation. Medical history included chronic migraines. Concomitant medications included fluticasone propionate (FLONASE); taken for unknown indication from an unknown date and unknown if ongoing. The patient previously received clarithromycin (BIAXIN) and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 22Apr2021 at 15:00, the patient experienced loss of smell. The event did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event loss of smell was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Headache, Nausea, Pain
Clinical narrative: Body aches; Fever (100.4 - 101.1); Chills\ shivering; Shaking; Intense headache; Waves of nausea; Injection site soreness; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) via an unspecified route of administration in the right arm on 22Apr2021 at 13:00 (at the age of 51-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medication within two weeks of vaccination. The patient had no known allergies. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) via an unspecified route of administration in the right arm on 01Apr2021 at 13:00 hours (at the age of 51-year-old) as a single dose for COVID-19 immunisation. On 22Apr2021 at 23:45, the patient experienced fever (100.4 - 101.1), chills\shivering, shaking, intense headache, waves of nausea, injection site soreness and body aches. On 22Apr2021, the patient underwent body temperature and the result was 100.4 - 101.1 (unspecified units). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the adverse events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event fever (100.4 to 101.1), chills\shivering, shaking, intense headache, waves of nausea, injection site soreness and body aches was recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia, Tremor, Vaccination site pain
Clinical narrative: Body aches; Fever (100.4 - 101.1); Chills\ shivering; Shaking; Intense headache; Waves of nausea; Injection site soreness; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) via an unspecified route of administration in the right arm on 22Apr2021 at 13:00 (at the age of 51-year-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient did not receive any medication within two weeks of vaccination. The patient had no known allergies. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: unknown) via an unspecified route of administration in the right arm on 01Apr2021 at 13:00 hours (at the age of 51-year-old) as a single dose for COVID-19 immunisation. On 22Apr2021 at 23:45, the patient experienced fever (100.4 - 101.1), chills\shivering, shaking, intense headache, waves of nausea, injection site soreness and body aches. On 22Apr2021, the patient underwent body temperature and the result was 100.4 - 101.1 (unspecified units). The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the adverse events. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event fever (100.4 to 101.1), chills\shivering, shaking, intense headache, waves of nausea, injection site soreness and body aches was recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: Joint swelling, Neuralgia
Clinical narrative: Nerve pain; Joint swelling; This is a spontaneous report from a contactable consumer, the patient. A 37-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EE0164) in the left arm on 15Apr2021 at 15:00 (at the age of 37-years-old) as a single dose for COVID-19 immunisation. Medical history included gallbladder removal, gluten allergy, dairy allergy and allergy to most antibiotic medications. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included birth control and cetirizine hydrochloride (ZYRTEC); both for unknown indication from unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 15Apr2021, at 15:30 the patient experienced nerve pain and joint swelling. Since the vaccination the patient not been tested for COVID-19. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of the reported events. The clinical outcome of the events nerve pain and joint swelling was recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Dysgeusia
Clinical narrative: Metal taste in mouth; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Unknown) via an unspecified route of administration in the right arm on 25Mar2021 at 09:30 (at the age of 53-years-old) as a single dose for COVID-19 immunisation. The patient had no past medical history. The patient had no known allergies to medications, food or other products. The patient did not receive any medication within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 25Mar2021 at 10:00, the patient experienced metal taste in mouth. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the event. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event metal taste in mouth was not recovered at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.